GMT Capital’s Niagen Bioscience NAGE Stock Holding History

GMT Capital’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-296,905	Closed	-$433K	–	102
2023 Q3	$433K	Hold	296,905	–	–	0.02%	95
2023 Q2	$466K	Hold	296,905	–	–	0.02%	83
2023 Q1	$454K	Buy	+296,905	New	+$529K	0.02%	73

Other funds holding NAGE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return

Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GMT Capital's NAGE Position: Q4 2023 in Review

GMT Capital sold out of Niagen Bioscience (NAGE) in Q4 2023, closing a stake of 296,905 shares — an estimated $433K sold.

GMT Capital first reported a position in NAGE in Q1 2023 and held it in 3 quarters. The position peaked at $466K in Q2 2023. 53 funds tracked by Wall St. Rank hold NAGE as of Q4 2023.

GMT Capital reported no remaining Niagen Bioscience position as of Q4 2023 after selling out during the quarter.
GMT Capital sold 296,905 Niagen Bioscience shares in Q4 2023, an estimated $433K.
GMT Capital first reported a position in Niagen Bioscience in Q1 2023 and held it in 3 quarters.
GMT Capital's Niagen Bioscience position peaked at $466K in Q2 2023.
53 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2023.

Based on GMT Capital's 13F filing for Q4 2023, filed 12 Feb 2024.